IRIS Accounts Production v24.3.2.46 15316256 director 29.11.23 31.12.24 31.12.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh153162562023-11-28153162562024-12-31153162562023-11-292024-12-31153162562023-11-2815316256ns15:EnglandWales2023-11-292024-12-3115316256ns14:PoundSterling2023-11-292024-12-3115316256ns10:Director12023-11-292024-12-3115316256ns10:PrivateLimitedCompanyLtd2023-11-292024-12-3115316256ns10:SmallEntities2023-11-292024-12-3115316256ns10:AuditExempt-NoAccountantsReport2023-11-292024-12-3115316256ns10:SmallCompaniesRegimeForDirectorsReport2023-11-292024-12-3115316256ns10:SmallCompaniesRegimeForAccounts2023-11-292024-12-3115316256ns10:FullAccounts2023-11-292024-12-3115316256ns10:CompanySecretary12023-11-292024-12-3115316256ns10:RegisteredOffice2023-11-292024-12-3115316256ns5:CurrentFinancialInstruments2024-12-3115316256ns5:ShareCapital2024-12-3115316256ns5:RetainedEarningsAccumulatedLosses2024-12-3115316256ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-31
REGISTERED NUMBER: 15316256 (England and Wales)















Unaudited Financial Statements

for the Period 29 November 2023 to 31 December 2024

for

Venipharm Ltd

Venipharm Ltd (Registered number: 15316256)






Contents of the Financial Statements
for the Period 29 November 2023 to 31 December 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Venipharm Ltd

Company Information
for the Period 29 November 2023 to 31 December 2024







DIRECTOR: E Mauger





SECRETARY: Pramex International Ltd





REGISTERED OFFICE: 8th Floor South
11 Old Jewry
London
EC2R 8DU





REGISTERED NUMBER: 15316256 (England and Wales)






Venipharm Ltd (Registered number: 15316256)

Balance Sheet
31 December 2024

Notes £   
CURRENT ASSETS
Debtors 4 166,073
Cash at bank 128,159
294,232
CREDITORS
Amounts falling due within one year 5 282,430
NET CURRENT ASSETS 11,802
TOTAL ASSETS LESS CURRENT
LIABILITIES

11,802

CAPITAL AND RESERVES
Called up share capital 10,000
Retained earnings 1,802
SHAREHOLDERS' FUNDS 11,802

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 24 March 2025 and were signed by:



E Mauger - Director


Venipharm Ltd (Registered number: 15316256)

Notes to the Financial Statements
for the Period 29 November 2023 to 31 December 2024

1. STATUTORY INFORMATION

Venipharm Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Venipharm Ltd (Registered number: 15316256)

Notes to the Financial Statements - continued
for the Period 29 November 2023 to 31 December 2024

2. ACCOUNTING POLICIES - continued

Going concern
The company is dependent upon the continued financial support of its parent company which has undertaken to financially support the company for the at least 12 months after the date of the signing of these accounts and for the foreseeable future.

The financial statements have therefore been prepared on a going concern basis.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 .

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Amounts owed by group undertakings 155,482
Other debtors 10,591
166,073

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Trade creditors 13,745
Amounts owed to group undertakings 242,023
Taxation and social security 927
Other creditors 25,735
282,430

6. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting
Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of
Ireland', not to disclose related party transactions with wholly owned subsidiaries within the
group.

7. ULTIMATE CONTROLLING PARTY

The immediate parent undertaking is Calonne SAS, a company registered in France. The
address of its registered office is 4 Bureaux de la colline, Saint cloud, France, 92210.